BAB V. SIMPULAN DAN SARAN
B. SARAN
1. Pasien PPOK stabil grup C dan D yang belum mengalami perbaikan secara optimal dengan terapi standar dapat dipertimbangkan untuk diberikan
allopurinol 300 mg/hari selama empat minggu sebagai tatalaksana farmakologi tambahan lebih lanjut guna meningkatkan kapasitas latihan serta perbaikan gejala klinis.
2. Penelitian lebih lanjut masih diperlukan untuk membuktikan apakah
DAFTAR PUSTAKA
1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Capetown: Global Initiative for Chronic Obstructive Lung Disease Inc; 2017. p. 1-123.
2. Senior RM, Pierce RA, Atkinson J. Chronic obstructive pulmonary disease:
epidemiology, pathophysiology, pathogenesis, and α1-antitrypsin deficiency. In: Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior R, editors. Fishman’s pulmonary diseases and disorders. 5th ed. New York: McGraw-Hill Education; 2015. p. 613-45.
3. Amin M, Yunus F, Antariksa B, Djajalaksana S, Wiyono W, editors. PPOK Diagnosis Dan Penatalaksanaan. 1st ed. Jakarta: Penerbit Universitas Indonesia; 2016. p. 1-111.
4. Antariksa B, Sitompul A, Ginting A, Hasan A, Tanuwihardja B, editors. PPOK Diagnosis Dan Penatalaksanaan. 2nd ed. Jakarta: Perhimpunan Dokter Paru Indonesia; 2011. p.1-88.
5. Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov. 2013;12(7):543-59.
6. Rahman I. Pharmacological antioxidant strategies as therapeutic interventions for COPD. Biochim Biophys Acta. 2012;1822(5):714-28.
7. Hakim A, Adcock IM, Usmani OS. Corticosteroid resistance and novel anti-inflammatory therapies in chronic obstructive pulmonary disease current evidence and future direction. Drugs. 2012;72(10):1299-312.
8. Cavalcante AG, de Bruin PF. The role of oxidative stress in COPD: current concepts and perspectives. J Brass Pneumol. 2009;35(12):1227-37.
9. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009;360:2445-54.
10. Pirabbasi E, Cheragi M. Antioxidant supplementation among COPD: is it necessary? Pakistan J Nutr. 2012;11(5):501-6.
response in COPD: Where do we stand? Mediators Inflamm. 2013;2013:1-9. 12. Kirkham PA, Barnes PJ. Oxidative stress in COPD. Chest.
2013;144(1):266-73.
13. Pouwels SD, Heijink IH, Hacken NHT. DAMPs activating innate and adaptive immune responses in COPD. 2013;10:1-12.
14. Heunks LMA, Dekhuijzen PNR. Respiratory muscle function and free radicals: from cell to COPD. Thorax. 2000;55(8):704-16.
15. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87-114.
16. Ryan MJ, Jackson JR, Hao Y, Leonard SS, Alway SE. Inhibition of xanthine oxidase reduces oxidative stress and improves skeletal muscle function in response to electrically stimulated isometric contractions in aged mice. Free Radic Biol Med. 2011;51(1):38-52.
17. MacNee W. COPD: pathology, pathogenesis, and pathophysiology. In: Currie G, editor.ABC of COPD. 1st ed. New York: Blackwell Publishing Company; 2006. p. 1202-30.
18. Ichinose M, Sugiura H, Yamagata S, Koarai A, Tomaki M, et al. Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways. Eur Respir J. 2003;22(3):457-61.
19. Barnes P. Chronic obstructive pulmonary disease: effects beyond the lungs. PLOS Med. 2010;7(3):1-4.
20. Macnee W, Vestbo J, Agusti A. COPD: pathogenesis and natural history. In: Broaddus VC, Mason RJ, Ernst JD, King TE, Lazarus RC, Murray JF, et al, editors. Murray & Nadel’s textbook of respiratory medicine. 6th ed. Philadelpia: Elsevier Saunders; 2016. p. 751-89.
21. Barnes PJ, Rennard S. Patophysiology of COPD. In: Barnes PJ, Drazen J, Rennard S, Thomson N, editors. Asthma and COPD: basics mechanism and clinical management. 1st ed. San Diego: Elsevier Inc.; 2009. p. 425-44. 22. Jardins TD, Burton GG. Clinical manifestations and assessment of respiratory
164-78.
23. West JB. Respiratory pathophysiology the essentials. 8th ed. Taylor C, editor. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 48-58.
24. Currie GDJ. COPD: non pharmacological management. In: Currie G, editor. ABC of COPD. 1st ed. New York: Blackwell Publishing Company; 2007. p. 1379-87.
25. Kirkham P, Rahman I. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol Ther. 2006;111(2):476-94.
26. Marwick JA, Ito K, Adcock IM, Kirkham PA. Oxidative stress and steroid
resistance in asthma and COPD : pharmacological manipulation of HDAC-2 as a therapeutic strategy. Ther target. 2007;11:745-55.
27. Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. Int J COPD. 2011;6(1):413-21.
28. Daheshia M. Pathogenesis of chronic obstructive pulmonary disease (COPD). Clin Appl Immunol Rev. 2005;5(5):339-51.
29. Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):71-86.
30. Stockley RA, Mannino D, Barnes PJ. Burden and pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009;6(6):524-6.
31. Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol. 2009;71:451-64.
32. Roca M, Verduri A, Corbetta L, Clini E, Fabbri LM, Beghé B. Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease. Eur J Clin Invest. 2013;43(5):510-21.
33. Doherty DE, Briggs DD. Chronic obstructive pulmonary disease: Epidemiology, pathogenesis, disease course, and prognosis. Clin Cornerstone. 2004;6(2 SUPPL. 1):5-16.
34. Nurwidya F, Damayanti T, Yunus F. The role of innate and adaptive immune cells in the immunopathogenesis of chronic obstructive pulmonary disease. Tuberc Respir Dis. 2016;79:5-13.
35. Ottenheijm CAC, Heunks LMA, Dekhuijzen R. Diaphragm adaptations in patients with COPD. Respir Res. 2008;14:1-14.
36. Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev drug Discov. 2013;(June):1-17.
37. Chung KF. Inflammatory Mediators in Chronic Obstructive Pulmonary Disease. 2005:619-625.
38. Ottenheijm CAC, Heunks LMA, Dekhuijzen P. Diaphragm muscle fiber dysfunction in COPD toward a pathophysiological concept. Am J Respir Crit Care Med. 2007;175:1233-40.
39. Holloway RA, Donnelly LE. Immunopathogenesis of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2013;19(2):95-102.
40. Voelkel NF, Gomez-Arroyo J, Mizuno S. Chronic obstructive lung disease/emphysema: the vascular story. Pulmo Circ. 2011; 1(3):320-6.
41. Lang F. Respiration, acid-base balance. In: Silbernagl S, Lang F, editors. Color atlas of pathophysiology. 1st ed. New York: Thieme; 2000. p. 66-79. 42. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive
pulmonary disease. Lancet. 2004;364:709-21.
43. Hyatt R. Spirometry: dynamic lung volumes. In: Hyatt RE, Scanlon PD, Nakamura M, editors. Interpretation of pulmonary function test: a practical guide. 4th ed. Philadelpia: Walters Kluwer Health; 2014. p. 4-22.
44. Hellebrandová L, Chlumský J, Vostatek P, Novák D, Rýznarová Z, Bunc V. Airflow limitation is accompanied by diaphragm dysfunction. Physiol Res. 2016;65:469-79.
45. Scanlon PD, Nakamura M. Simple tests of exercise capacity. In: Hyatt RE, Scanlon PD, Nakamura M, editors. Interpretation of pulmonary function test: a practical guide. 4th ed. Philadelpia: Wolters Kluwer Health; 2014. p. 87-98. 46. Chuang ML, Lin IF, Lee C. Clinical assessment tests in evaluating patients
with chronic obstructive pulmonary disease. Medicine.2016;47:1-7.
47. Des Jardins T. Pulmonary function measurements. In: Des Jardins T, editor. Cardiopulmonary anatomy and physiology: essential for respiratory care. 4th ed. New York: Thomsom Learning; 2002. p. 144-61.
48. Celli BR, Cote CG, Marin JM, Casanova C, de Oca MM, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005-12.
49. Macario CC, Celli B. Should we be paying attention to inspiratory capacity? Arch Bronconeumol. 2007;43(5):245-7.
50. Parmar D. Benefits of inspiratory muscle training in COPD patients. Int J Sci Res.2015;4(9):680-4.
51. Crisafulli E, Clini E. Measures of dyspnea in pulmonary rehabilitation. Multidiscip Respir Med. 2010;5(3):202-10.
52. Karloh M, Palu M, Mayer A. Methods for assessing functional capacity in patients with COPD. Con Sci Saude. 2014;13(4):633-49.
53. Bailey P. The dyspnea-anxiety-dyspnea cycle COPD patients ’stories of breathlessness: “it’s scary/when you can’t breathe.” Qual. Health Res. 2014;14(6):760-78.
54. Okutan O, Tas D, Demirer E, Kartaloglu Z. Evaluation of quality of life with the chronic obstructive pulmonary disease assessment test in chronic obstructive pulmonary disease and the effect of dyspnea on disease-specific quality of life in these patients. Yonsei Med J. 2013;54(5):1214-19.
55. Lan CC, Chu W, Yang MC, Lee CH, Wu Y. Benefits of pulmonary rehabilitation in patients with COPD with normal exercise capacity. Respir. Care.2013;4(2):1-23.
56. Ottenheijm CAC, Heunks LMA, Sieck GC, Zhan WZ, Jansen SM, Degens H. Diaphragm dysfunction in chronic obstructive pulmonary disease. Am J Res Crit Care Med.2005;172:200-6.
57. Enright P. The Six-Minute Walk Test. Respir Care. 2003;48:783-5.
58. Rasekaba T, Lee AL, Naughton MT, Williams TJ, Holland AE. The six-minute walk test: a useful metric for the cardiopulmonary patient. Intern Med J. 2009;39(8):495-501.
59. Bolton CE, Bevan-Smith EF, Blakey JD, Crowe P, Elkin SL et al. British Thoracic Society guideline on pulmonary rehabilitation in adults. Thorax.
2013;68(Suppl 2):ii1-30.
60. Rochester CL, Vogiatzis I, Holland AE, Lareau SC, Marciniuk DD, Spruit M. An official American Thoracic Society/European Respiratory Society policy statement: enhancing implementation, use, and delivery of pulmonary rehabilitation. Am J Respir Crit Care Med.2015;192:1373-86.
61. Spruit MA, Singh SJ, Garvey C, Zuwallack R, Nici L, Rochester C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):13-64.
62. Coxson H. Quantitative imaging of the lung. In: Barnes P, Drazen J, Rennard S, Thomson N, eds. Asthma and COPD: Basics Mechanism and Clinical Management. 2nd ed. San Diego: Elsevier Inc.; 2009:559-68.
63. Karnati S. Diagnosis and markers for the assessment of COPD; can a consensus be reached. PVRI Chron J. 2017;3(2):40-46.
64. Camillo CA, Osadnik CR, Remoortel HV, Burtin C, Janssens W, Troosters T.
Effect of “add-on” interventions on exercise training in individuals with
COPD: a systematic review. ERJ Open. 2016;2:1-14.
65. Galanter JM, Boushy HA. Drugs used in asthma. In: Katzung BG, Trevor aj, editros. Basic and clinical pharmacology. 13th ed. New York: McGraw-Hill; 2015. p. 336-54.
66. Nardini S, Camiciottoli G, Locicero S, Maselli R, Pasqua F, Pela GR, et al. COPD: maximization of bronchodilation. Multidiscip Respir Med. 2014;9(1):50-60.
67. Latorre M, Novelli F, Vagaggini B, Braido F, Papi A, Sanduzi A, et al. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS. Pulm Pharmacol Ther. 2015;30(11):44-50.
68. Cazzola M, Page CP, Calzetta L, Matera MG. Emerging anti-inflammatory strategies for COPD. Eur Respir J. 2012;40(3):724-741.
maintenance schedules following pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomised controlled trial. BMJ Open. 2015;5:1-19.
70. Lee AL, Holland A. Time to adapt exercise training regimens in pulmonary rehabilitation-a review of the literature. Int J COPD. 2014;9:1275-88.
71. Wells BG, DiPiro JT, Schwinghammer TL, Hamilton CW. Gout and hyperuricemia. In: Wells BG, DiPiro JT, Schwinghammer TL, Hamilton CW, editors. Pharmacotherapy handbook. 6th ed. Philadelphia: McGraw-Hill;2006. p. 1-6.
72. Lüllmann H, Mohr K, Ziegler A, Bieger D. Therapy of selected diseases. In: Lüllmann H, Mohr K, Ziegler A, Bieger D, editors. Color atlas of pharmacology. 2nd ed. Stuttgart: Thieme; 2000:316-7.
73. Duncan R, Aronson J. Musculoskeletal and joints. In: Duncan R, Aronson J, editors. Oxford handbook of practical drug therapy. 1st ed. Oxford: Oxford University Press;2005. p. 566-7.
74. Heunks LMA, Vina J, van Herwaarden CLA, Folgering HTM, Gimeno A, et al. Xanthine oxidase is involved in exercise-induced oxidative stress in chronic obstructive pulmonary disease. Am J Physiol. 1999;277:R1697-704. 75. Delample D, Durand F, Severac A, Belghith M, Mas E, et al. Implication of
xanthine oxidase in muscle oxidative stress in COPD patients. Free Radic Res. 2008;42(9):807-14.
76. Dahlan M. Menentukan besar sampel. In: Susila A, ed. Besar Sampel Dan Cara Pengambilan Sampel. 3rd ed. Jakarta: Salemba Medika; 2010. p. 19-24. 77. Scherer TA, Spengler CM, Owassapian D, Imhof E, Boutellier URS.
Respiratory muscle endurance training in chronic obstructive pulmonary disease: impact on exercise capacity, dyspnea, and quality of life. Am J Respir Crit Care Med. 2000;162(5):1709-14.
78. Raharjo A. Pengaruh latihan harmonika pada kapasitas inspirasi, gejala sesak napas, kapasitas latihan, dan kualitas hidup penderita PPOK. [Thesis]. Departement of Pulmonology and Respiratory Medicine Medical Faculty: Sebelas Maret University; 2017.
79. Widyastuti K. Pengaruh exercise berjalan berbasis pedometer dan standar terhadap aktivitas fisik, gejala sesak napas, kapasitas exercise, dan kualitas hidup penderita PPOK stabil. [Thesis]. Departement of Pulmonology and Respiratory Medicine Medical Faculty: Sebelas Maret University; 2017. 80. Mustadi W. Pengaruh pemberian L-Carnitine terhadap kadar asam laktat,
6MWT, % VEP1, dan skor CAT penderita PPOK stabil. [Thesis]. Departement of Pulmonology and Respiratory Medicine Medical Faculty: Sebelas Maret University; 2016.
81. Ghezzi P. Role of glutathione in immunity and inflammation in the lung. Int J Gen Med. 2011;4:105-13.
82. Morris D, Khurasany M, Nguyen T, Kim J, Guilford F, Mehta R, et al. Glutathione and infection. Biochim Biophys Acta - Gen Subj. 2013;1830(5):3329-49.
83. Deneke S, Fanburg B. Regulation of cellular glutathione. Am J Physiol Soc. 1989;257:L163-73.
84. Wu G, Fang Y, Yang S, Lupton JR, Turner ND. Recent Advances in Nutritional Sciences Glutathione metabolism and its implications for health 1. Environ Heal. 2004;134(December 2003):489-92.
85. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European respiratory society/American thoracic society technical standard: Field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1428-46.
86. Kon SSC, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, et al. Minimum clinically important difference for the COPD assessment test: A prospective analysis. Lancet Respir Med. 2014;2(3):195-203.
87. Karloh M, Mayer AF, Maurici R, Pizzichini MMM, Jones PW, Pizzichini E. The COPD assessment test: what do we know so far? a systematic review and meta-analysis about clinical outcomes prediction and classification of patients into gold stages. Chest. 2016;149(2):413-25.
88. Puspitasari Y. Peran erdosteine pada derajat obstruksi dan skor COPD assessment test (CAT) penderita PPOK stabil. [Thesis]. Departement of
Pulmonology and Respiratory Medicine Medical Faculty: Sebelas Maret University; 2015.
89. Smid DE, Franssen FME, Houben-Wilke S, Vanfleteren LEGW, Janssen DJA, Wouters EFM, et al. Responsiveness and MCID estimates for CAT, CCQ, and HADS in patients with COPD undergoing pulmonary rehabilitation: a prospective analysis. J Am Med Dir Assoc. 2017;18(1):53-8.
A. Lampiran 1. Jadwal Pelaksanaan Penelitian